Behavioural and psychiatric phenotypes in female carriers of genetic mutations associated with X-linked ichthyosis.
Adult
Attention Deficit Disorder with Hyperactivity
/ pathology
Case-Control Studies
Female
Heterozygote
Humans
Ichthyosis, X-Linked
/ genetics
Male
Mothers
/ psychology
Phenotype
Polymorphism, Genetic
Postpartum Period
Pregnancy
Psychometrics
Self Report
Steryl-Sulfatase
/ genetics
Surveys and Questionnaires
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
23
07
2018
accepted:
31
01
2019
entrez:
16
2
2019
pubmed:
16
2
2019
medline:
19
11
2019
Statut:
epublish
Résumé
X-linked ichthyosis (XLI) is a rare X-linked dermatological condition arising from deficiency for the enzyme steroid sulfatase (STS). STS is normally expressed in the brain, and males with XLI exhibit personality differences from males in the general population, and are at increased risk of developmental and mood disorders. As the STS gene escapes X-inactivation, female carriers of XLI-associated genetic mutations have reduced STS expression/activity relative to non-carrier females, and could manifest similar behavioural phenotypes to males with XLI. Additionally, as STS activity normally increases in female tissues towards late pregnancy and into the puerperium, carrier females could theoretically present with increased rates of postpartum psychopathology. Using a worldwide online survey comprising custom-designed demographic questionnaires and multiple validated psychological questionnaires, we collected detailed self-reported information on non-postpartum and postpartum behaviour in confirmed adult (>16yrs) female carriers of genetic mutations associated with XLI (n = 94) for statistical comparison to demographically-matched previously-published normative data from female controls (seven independent studies, 98≤n≤2562), adult males with XLI (n = 58), and to newly-obtained online survey data from a general population sample of mothers from the United Kingdom and United States of America (n = 263). The pattern of results in carrier females relative to controls was remarkably similar to that previously observed in males with XLI, with evidence for increased rates of developmental and mood disorders, and elevated levels of inattention, impulsivity, autism-related traits and general psychological distress. Carrier females exhibited a significantly elevated rate of postpartum mental health conditions (notably mild depression) relative to controls which could not be accounted for by social factors. Our data confirm the psychological profile associated with XLI-associated mutations, and suggest that female carriers may be at increased risk of psychopathology, including in the postpartum period. These findings are relevant to families affected by XLI, to clinicians involved in the care of these families, and to genetic counsellors.
Identifiants
pubmed: 30768640
doi: 10.1371/journal.pone.0212330
pii: PONE-D-18-21803
pmc: PMC6377116
doi:
Substances chimiques
STS protein, human
EC 3.1.6.2
Steryl-Sulfatase
EC 3.1.6.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0212330Subventions
Organisme : Medical Research Council
ID : MR/L010305/1
Pays : United Kingdom
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Brain Res. 1973 Sep 14;59:349-58
pubmed: 4747761
Exp Dermatol. 2019 Oct;28(10):1156-1163
pubmed: 29672931
Psych J. 2013 Apr;2(1):48-62
pubmed: 24294490
JAMA Psychiatry. 2018 Aug 1;75(8):835-843
pubmed: 29898212
J Med Genet. 2008 Aug;45(8):519-24
pubmed: 18413370
Genes Brain Behav. 2011 Apr;10(3):334-44
pubmed: 21255266
Neuropsychopharmacology. 2012 Apr;37(5):1267-74
pubmed: 22189290
Aust N Z J Psychiatry. 2011 Apr;45(4):308-16
pubmed: 21332432
J Autism Dev Disord. 2001 Feb;31(1):5-17
pubmed: 11439754
Orphanet J Rare Dis. 2016 Nov 9;11(1):151
pubmed: 27829465
Nature. 2005 Mar 17;434(7031):400-4
pubmed: 15772666
Psychol Med. 2002 Aug;32(6):959-76
pubmed: 12214795
Birth. 2017 Dec;44(4):369-376
pubmed: 28594092
Nat Rev Dis Primers. 2018 Apr 26;4:18022
pubmed: 29695824
Am J Hum Genet. 2009 Apr;84(4):524-33
pubmed: 19344873
J Mol Endocrinol. 2018 Aug;61(2):T199-T210
pubmed: 29440314
Acta Psychiatr Scand. 2006 Jul;114(1):55-61
pubmed: 16774662
Mol Autism. 2014 Mar 06;5(1):21
pubmed: 24602487
Trends Mol Med. 2012 May;18(5):256-62
pubmed: 22475435
Psychoneuroendocrinology. 2016 Dec;74:363-370
pubmed: 27728876
Psychoneuroendocrinology. 2012 Feb;37(2):221-9
pubmed: 21723668
J Psychiatr Res. 2000 May-Jun;34(3):221-6
pubmed: 10867117
Psychol Med. 2005 Feb;35(2):245-56
pubmed: 15841682
Biol Psychiatry. 2007 Jun 15;61(12):1351-60
pubmed: 17161381
Psychol Med. 2010 Feb;40(2):225-37
pubmed: 19531277
J Am Acad Dermatol. 2015 Apr;72(4):617-27
pubmed: 25659225
PLoS One. 2014 Jul 16;9(7):e102251
pubmed: 25029203
Arch Gen Psychiatry. 2011 May;68(5):459-65
pubmed: 21536975
J Obstet Gynaecol Can. 2014 Sep;36(9):803-810
pubmed: 25222359
Schizophr Bull. 1991;17(4):555-64
pubmed: 1805349
Biol Psychiatry. 2018 Oct 15;84(8):555-562
pubmed: 29861095
Psychoneuroendocrinology. 2013 Aug;38(8):1370-80
pubmed: 23276394
Biol Psychiatry. 2009 Aug 15;66(4):360-7
pubmed: 19251250
Neuropsychopharmacology. 2014 Oct;39(11):2622-32
pubmed: 24842408
J Am Acad Dermatol. 2010 Mar;62(3):480-5
pubmed: 20080321
Behav Brain Funct. 2007 May 21;3:24
pubmed: 17517138
Br J Dermatol. 2018 Oct;179(4):933-939
pubmed: 29901853
J Clin Psychol. 1995 Nov;51(6):768-74
pubmed: 8778124
Br J Psychiatry. 2009 Mar;194(3):204-11
pubmed: 19252145
PLoS One. 2016 Oct 6;11(10):e0164417
pubmed: 27711218
Prenat Diagn. 2010 Sep;30(9):893-8
pubmed: 20715120
Pediatr Endocrinol Rev. 2012 May;9 Suppl 2:710-2
pubmed: 22946281
J Med Case Rep. 2017 Sep 22;11(1):267
pubmed: 28934990
Acta Derm Venereol. 1999 Mar;79(2):143-4
pubmed: 10228635
Clin Genet. 1999 Jun;55(6):455-60
pubmed: 10450863